Previous 10 | Next 10 |
Trial met both primary endpoints demonstrating statistically significant and clinically meaningful extension of progression free survival (PFS) as monotherapy vs. standard of care (SoC) endocrine therapy in overall population and estrogen receptor mutation (mESR1) population In the ...
Radius Health (NASDAQ:RDUS) has lost ~34.2% in the post-market after the company announced that its Phase 3 trial for abalo-TDS in postmenopausal women with osteoporosis did not meet the primary endpoint. The wearABLe study was designed to evaluate the non-inferiority (NI) abalo-TDS...
The wearABLe study did not demonstrate non-inferiority of abalo-TDS to TYMLOS® Lumbar spine BMD at 12 months vs. baseline for abalo-TDS was +7.1% vs. TYMLOS +10.9% Both abalo-TDS and TYMLOS 12-month results are considered clinically meaningful Abalo-TDS was well tolerat...
BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) announced it will host a conference call today, Wednesday, December 8, 2021, at 4:00 p.m. ET to cover the below: Discuss topline results from the wear...
BOSTON, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that management will participate in the Stifel 2021 Virtual Healthcare Conference, including a fireside chat at 8:40 a.m. ET on Tuesday, Novem...
The following slide deck was published by Radius Health, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Radius Health, Inc. 2021 Q3 - Results - Earnings Call Presentation
Radius Pharmaceuticals, Inc. (RDUS) Q3 2021 Earnings Conference Call November 8, 2021, 08:30 AM ET Company Participants Kelly Martin – CEO Chhaya Shah – Vice President Ethan Holdaway – Head of Investor Relations Steve Helwig – Finance and Accounting Officer Bob Val...
Radius Health shares slide (RDUS -7.6%) after the company reported third-quarter revenue and profit that missed Wall Street estimates. Quarterly revenue decreased 27% to $56.81M, missing analysts' average estimate by $4.46M. The company also updated its FY forecast: TYMLOS net revenue FY...
Radius Health (NASDAQ:RDUS): Q3 Non-GAAP EPS of -$0.32 misses by $0.24; GAAP EPS of -$0.47 misses by $0.23. Revenue of $56.81M (-27.0% Y/Y) misses by $4.46M. Press Release For further details see: Radius Health EPS misses by $0.24, misses on revenue
TYMLOS ® Q3, 2021 net revenue: $57 million, +13% vs. Q3, 2020 Added 4,461 new patients on TYMLOS in Q3, 2021, +10% vs. Q3, 2020 Adjusted EBITDA of ($11) million vs. $9 million in Q3, 2020 which included elacestrant license revenue ATOM Pivotal Study evaluating abalopa...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 54.4% to $0.4264 on volume of 158,036,142 shares Versus Systems Inc. (VS) rose 73.5% to $2.29 on volume of 40,036,424 shares Tesla Inc. (TSLA) rose 5.3% to $220.97 on volume of 32,375,487 shar...
Ferrous, Nonferrous and Finished Steel Sales Volumes Up Sequentially Radius Board Declares Quarterly Dividend PORTLAND, Ore., July 02, 2024 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ: RDUS) today reported results for the third quarter of fiscal 2024 ended May 31, 2024. ...